Mesothelioma
Types
Pleural Mesothelioma
Peritoneal Mesothelioma
Mesothelioma glossary
Asbestos Imports
|
Malignant pleural mesothelioma
AUTHOR: Ho L, Sugarbaker DJ, Skarin AT
TITLE: Malignant pleural mesothelioma.
SOURCE: Cancer Treat Res; 105:327-73 2001 UI: 21117699
ABSTRACT: Malignant pleural mesothelioma remains a difficult
tumor to treat, much less cure. Currently, the best chance for long-term
survival lies with early diagnosis and aggressive surgical extirpation,
but given the typically long delay between the onset of symptoms and diagnosis,
this is only possible with a high index of suspicion and an aggressive
diagnosis workup. Early referral to a tertiary center experienced in the
treatment of MPM may be important for several reasons:
(1) decreased risk of tumor spread along multiple thoracenesis/biopsy
tracts,
(2) the availability of specialized pathologic assays for definitive diagnosis,
(3) the availability of critical staging modalities (aggressive mediastinoscopy
+/- thoracoscopy, MRI scans performed according to specific mesothelioma
protocols, and perhaps PET scans),
(4) surgical experience with pleurectomy/decortication and/or extrapleural
pneumonectomy, that may decrease morbidity and mortality, and
(5) the availability of novel adjuvant protocols.
Single-modality therapy is unlikely to result in long-term survival.
Aggressive surgery is required for optimal debulking, and extrapleural
pneumonectomy may offer better local control compared with pleurectomy/ecortication.
Delivery of optimal radiation schedules, which may involve large fractions
as well as large total doses, is limited by the presence of nearby dose-limiting
structures. Current chemotherapy is severely lacking in producing objective
responses and improved survival although gemcitabine and IL-2 may be active
agents to be combined with radiation and/or other agents. Hyperthermia,
photodynamic therapy, intracavitary therapy, and gene therapy are all
relatively new techniques under active investigation that should be supported
by enrollment in on-going protocols. Predictably, many of these techniques
provide greater benefit when used in the setting of adjuvant protocols
or minimal residual disease, emphasizing the importance of multimodality
therapy.
To receive a FREE information packet, please fill out the following form (U.S. only please):
| Pleural Mesothelioma | Peritoneal Mesothelioma | Home | Pathogenesis | Genetic
susceptibility and asbestos exposure | Asbestos
Imports | |